BrainsWay (BWAY) Q4 2025: Backlog Surges 43% as Recurring Model Drives Revenue Visibility
BrainsWay exits 2025 with a 43% YoY increase in remaining performance obligations, reflecting robust enterprise demand for its deep TMS platform and a highly visible recurring revenue base. The company’s focus on long-term leasing agreements and minority investments in mental health networks is translating into both near-term margin gains and a durable growth runway. With FDA clearances expanding indications and accelerated protocols, management is signaling confidence in scaling adoption and optimizing pricing power into 2026.
Summary
- Recurring Revenue Model Delivers: Lease-driven contracts underpin margin expansion and multi-year growth visibility.
- Enterprise and Clinical Adoption Accelerates: Backlog and installed base expand as new indications and protocols gain traction.
- Strategic Investments Compound Growth: Minority stakes in mental health providers create a reinforcing cycle of device demand and ecosystem value.
Performance Analysis
BrainsWay delivered a year of strong execution, with revenue and profitability outpacing expectations on the back of its recurring lease model. The company shipped 95 deep TMS systems in Q4, growing its installed base to approximately 1,700 systems, a 26% increase from the prior year. The book-to-bill ratio improved to 1.4x, up from 1.2x last quarter, signaling sustained demand momentum. Gross margin expanded to 76% in Q4, and operating income scaled faster than revenue, reflecting disciplined cost management and operating leverage from the recurring model.
Remaining performance obligations (RPO), a key measure of contracted future revenue, surged 43% to $70 million, providing multi-year revenue visibility and validating the shift toward long-term enterprise leasing. Cash flow from operations was positive, and the company exited the year debt-free with $68 million in cash, supporting both core growth and strategic investments. Sales and marketing investment increased moderately, focused on commercial expansion, while R&D spend rose to support clinical pipeline and new protocol development.
- Lease Model Drives Margin Expansion: Recurring contracts enable revenue to scale faster than operating expenses, supporting 10 consecutive quarters of profitability.
- Backlog and RPO Signal Demand Strength: Book-to-bill ratio above 1 and RPO growth highlight robust enterprise and clinical adoption.
- Strategic Capital Allocation: Ongoing investment in minority stakes and pipeline innovation positions BrainsWay for ecosystem leverage and future indication expansion.
BrainsWay’s financial trajectory reflects a business model shift from one-time device sales to high-visibility, multi-year lease revenue, with management guiding for continued double-digit growth and margin expansion in 2026.
Executive Commentary
"This shift has enabled us to build highly attractive recurring revenue model. Today, the majority of our enterprise customers are signed on a long-term leasing agreement with a high rate of customer renewals. Overall, this model provides meaningful stability and visibility into our revenue and growth potential that extends for years into the future."
Hadar Levy, Chief Executive Officer
"Our capital structure remained debt-free, giving us significant flexibility to pursue strategic growth initiatives, including the investment program Adaro outlined earlier. Looking ahead, we are excited by the momentum in our business and the opportunities ahead."
Ido Marom, Chief Financial Officer
Strategic Positioning
1. Recurring Enterprise Model and Leasing Penetration
BrainsWay’s pivot to a recurring lease model with enterprise mental health providers is the company’s central growth engine. By prioritizing long-term contracts and renewals, the business has established a stable, predictable revenue base that supports margin expansion and cash flow resilience. The high renewal rates and installed base growth confirm customer stickiness and platform value.
2. Clinical Pipeline and Indication Expansion
FDA clearances for adolescent depression and new accelerated protocols broaden BrainsWay’s addressable market, while ongoing clinical studies in alcohol use disorder and neurology (Alzheimer’s, dementia) offer future upside. The SWIFT protocol, which reduces required clinic visits by 70%, is positioned to drive both patient access and provider adoption, particularly as payers begin to cover accelerated treatments.
3. Ecosystem Investments and Strategic Partnerships
Minority investments in mental health provider networks create a flywheel effect: capital enables partners to scale locations and patient volume, which in turn drives demand for BrainsWay systems and reinforces recurring revenue. The company’s initial investment in NeuroLive (wearable neuromodulation) signals intent to broaden its technology portfolio and integrate care modalities, supporting a multi-pronged ecosystem strategy.
4. Pricing Power and Differentiation
Management is signaling confidence in optimizing pricing, with no anticipated ASP declines and potential for premium pricing based on differentiated clinical outcomes and service. The company’s unique product positioning and customer support are cited as drivers of willingness to pay, reinforcing margin durability.
5. Regulatory and Payer Tailwinds
Recent wins in reimbursement policy, such as Evernorth’s removal of prior authorization for TMS, lower barriers to adoption and expand access. As more payers follow suit and coverage for new protocols expands, BrainsWay stands to benefit from both volume and utilization growth.
Key Considerations
BrainsWay’s Q4 results reflect a business at the intersection of clinical innovation, recurring revenue, and ecosystem leverage. The company’s strategy is to compound growth through both direct leasing and minority investments, while expanding its clinical and technology portfolio.
Key Considerations:
- Visibility from Backlog and RPO: The 43% YoY RPO growth provides multi-year revenue confidence and underpins management’s robust 2026 guidance.
- SWIFT Protocol as a Demand Catalyst: Accelerated treatment reduces friction for adoption, supporting higher patient throughput and retention for providers.
- Enterprise Focus Increases Stickiness: Long-term leasing and high renewal rates with large providers anchor recurring revenue and reduce churn risk.
- Pipeline and Indication Expansion: Ongoing trials in AUD and neurology, as well as new FDA clearances, set up additional growth vectors and market share gains.
- Strategic Investments Compound Core Growth: Minority stakes in provider networks deliver both system demand and equity value, reinforcing the ecosystem approach.
Risks
BrainsWay faces execution risk in scaling clinical adoption and ensuring payer coverage keeps pace with new protocols and indications. The company’s growth is increasingly tied to the success and expansion of minority investment partners, introducing exposure to their operational performance. Regulatory or reimbursement setbacks, slower-than-expected clinical trial enrollment, or competitive innovation in neuromodulation could impact momentum and margin trajectory. Management’s optimism around pricing power may be tested if competitive offerings or payer pressure intensify.
Forward Outlook
For Q1 2026, BrainsWay guided to:
- Continued revenue growth in line with the current trajectory
- Further margin expansion from operational leverage and recurring revenue
For full-year 2026, management raised guidance:
- Revenue of $66 to $68 million, representing 27% to 30% YoY growth
- Operating income margin of 13% to 14%
- Adjusted EBITDA of $12 to $14 million, up 86% to 100% YoY
Management highlighted several factors that support this outlook:
- Strong sales pipeline and RPO visibility
- New FDA clearances and payer wins accelerating adoption
Takeaways
BrainsWay’s execution on a recurring revenue model, clinical expansion, and ecosystem investments is compounding growth and building a durable competitive moat.
- Recurring Model Delivers Margin and Visibility: High renewal rates and lease penetration are translating into multi-year revenue confidence and operating leverage.
- Clinical and Ecosystem Flywheel: FDA clearances, payer policy changes, and minority investments reinforce demand and platform differentiation.
- Future Watchpoint: Monitor execution on clinical pipeline milestones, partner network performance, and pricing dynamics as the company scales into new indications and geographies.
Conclusion
BrainsWay exits 2025 with accelerating backlog, expanding profitability, and a strategic model built for recurring growth. The company’s focus on enterprise leasing, clinical innovation, and ecosystem investments positions it as a leader in neuromodulation with substantial upside potential as adoption scales.
Industry Read-Through
BrainsWay’s results and strategy provide a template for medtech and digital health peers navigating the shift from transactional device sales to recurring, service-driven models. The accelerating adoption of accelerated protocols and payer policy changes signal a broader industry tailwind for non-invasive neuromodulation and interventional psychiatry. Minority investments in provider networks highlight a growing trend of ecosystem integration and capital-enabled care expansion, which other device and digital health companies may emulate. As reimbursement for innovative protocols expands, companies with differentiated clinical evidence and platform breadth are best positioned to capture share in a rapidly evolving mental health landscape.